Latest Revenue Recognition News

UOA Development Bhd reported a 70% rise in quarterly revenue to RM221.2 million and a modest profit increase to RM95.6 million, driven by ongoing projects and robust new property sales.

FOS Capital reported a 12% revenue decline and an EBITDA loss of $0.5 million in FY26, impacted by softer market conditions and project delays. However, a $10 million order book and record $130 million pipeline set the stage for a potential turnaround in FY27.

Jcurve Solutions (ASX:JCS) posted a significant financial turnaround in FY2026, with revenue climbing 16.3% to $13.28 million and normalised EBITDA more than doubling to $1.88 million, underpinned by disciplined cost control and recurring revenue growth.

Tamawood Limited boosted its profit after tax by over 40% to $8.19 million in FY26 while maintaining a debt-free balance sheet and accelerating AI-driven operational efficiencies.

Etherstack posted a record $8.5 million in revenue for the first half of 2026, driven by strong project and support income, but statutory profit fell 67% due to front-loaded costs and higher expenses.

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Scott Technology has locked in NZ$20 million worth of new Materials Handling & Logistics contracts across North America and Europe, reinforcing its Destination 2030 growth strategy and building on strong FY26 momentum.

GR Engineering Services has locked in a $275 million EPC contract for the Yitirrti Copper-Silver-Zinc Project, reinforcing its position as a leading Australian minerals processing contractor.

Aurizon lifted FY2026 underlying EBITDA by 9% to $1.72 billion, boosted by strong Bulk growth and regulatory gains, while locking in a major Queensland coal haulage contract with BHP Mitsubishi Alliance.

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Audeara has reached a key milestone as its chip-level AI licensing partnership with Optek enters commercial production, receiving initial purchase orders worth about A$31,000. This validates Audeara’s scalable fee-per-chip licensing model and sets the stage for broader applications in audio and hearing health.